JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (1): 15-19.doi: 10.6040/j.issn.1671-7554.0.2012.566

• Articles • Previous Articles     Next Articles

Experimental study of anti-CD3/anti-EGFR bispecific antibody therapeutic activity against pancreatic cancer cells

ZHANG Lin1, HOU Yan-hong1, ZHANG Jian2, HU Jing1, ZHANG Jing1   

  1. 1. Department of Gastroenterology, the 309th Hospital of PLA, Beijing 100091, China;
    2. Department of Molecular Biology, the Fourth Military Medical University, Xi’an 710032, China;
  • Received:2012-08-20 Online:2014-01-10 Published:2014-01-10

PDF (PC)

600

Abstract:

Objective  To investigate the cytotoxicity of EGFR/CD3 bispecific antibody by chemical synthesis against pancreatic cancer cells in vitro. Methods  In previous researches, the EGFR/CD3 bispecific antibody was prepared by chemical synthesis. The cytotoxicity activity of this antibody against pancreatic cancer was analyzed by the cell combination rate assay and 51Cr assay. The cell cycle and apoptosis were analyzed by flow cytometry. Then the comparisions of the cytotoxicity activity between the bispecific antibody and EGFR mAb was conducted. Results  The biding rate of EGFR/CD3 bispecific antibody cell with effector cells PBLS and pancreatic cancer cell line SW1990 was high enough to satisfy the treatment demand.The lysis rate and apoptosis rate of cancer cells treated with immunological effector cells targeted by EGFR/CD3 bispecific antibody were higher than those of the  control groups significantly (P<0.05). The apoptosis rate of cancer cells increased. Conclusion  It is suggested that the cytotoxicity of effector cells could be enhanced by EGFR/CD3 bispecific antibody in vitro, so it has promising curative effect on pancreatic cancer.

Key words: Cellular immunotherapy, EGFR monoclone antibody, Pancreatic neoplasms, Bispecific antibody

[1] GULIBAHAER·Abulimiti1, GONG Xiao-jin1, GULINAER·Kuerban2. Expressions of MMP-9 and IL-6 in pancreatic neoplasm and  their relationships with clinical pathological classification [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 99-.
[2] ZHANG Hong-yu,FEI Li-ming,WANG Chang-liang,ZHAO Wen-hua,ZHANG Bo,ZHOU Wu-yuan,ZHONG Wei-xia,LI Sheng. Correlations of Syk with pathology and angiogenesis of pancreatic adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(9): 880-883.
[3]

CUI Ya-zhou,JIA Qing,WANG Zhao-peng,WANG Zhao-xia,TIAN Mei,ZHANG Yue-ying,ZHANG Wei-dong,HAN Jin-xiang

. A pancreatic cancer model with high liver metastatic potential in nude mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(8): 739-741.
[4] DONG Ning-ning,WANG Nan-da,ZHANG Fa-xue,LI Wen-hai,DIAO Yu-tao,LI Hui-qing,WANG Ming-yu. A trend of mortality of pancreatic cancer during 1985-2004 in rural area of Zhaoyuan County [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(10): 1007-1011.
[5] LI Yu-liang,WANG Yong-zheng,WANG Xiao-hua,ZHANG Fu-jun,ZHU Li-dong,ZHANG Wang-ming,LI Zheng,LI Zhen-jia,ZHANG Kai-xian. I implantation combined with Gemcitabine in the treatment of advanced pancreatic cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(4): 393-396.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd